- Home
- GLUE vs PSNY Comparison
GLUE vs PSNY Comparison
Compare GLUE & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | PSNY |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GLUE | PSNY |
|---|---|---|
| Price | $10.05 | $5.97 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 8 | 3 |
| Target Price | ★ $28.50 | $12.50 |
| AVG Volume (30 Days) | ★ 1.1M | 259.2K |
| Earning Date | 11-05-2026 | 09-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $123,672,000.00 | N/A |
| Revenue This Year | N/A | $3.84 |
| Revenue Next Year | N/A | $35.40 |
| P/E Ratio | $72.42 | ★ N/A |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $7.44 | $0.50 |
| 52 Week High | $25.77 | $23.75 |
Technical Indicators
Market Signals| Indicator | GLUE | PSNY |
|---|---|---|
| Relative Strength Index (RSI) | 20.05 | 18.69 |
| Support Level | N/A | N/A |
| Resistance Level | $25.38 | $8.15 |
| Average True Range (ATR) | 0.54 | 0.36 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 2.11 | 0.89 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About PSNY Polestar Automotive Holding UK PLC ADS
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.